Large Bio-Tech Manufacturer Enhances Program Efficiency

A large Bio-Tech manufacturer faced significant challenges due to a $50M FCPA enforcement settlement and issues with their previous third-party management software. The major problems were poor report quality, inadequate media screening results, and a depleted team due to COVID-19. To overcome these issues, the company turned to Diligent Third-Party Risk Management, which offered high-quality investigative reports, real-time monitoring, and automated processes.

    Share This